Condition: Solid Tumors Refractory to Standard Therapy · Sponsor: Rabin Medical Center
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors. The main questions it aims to answer are: * Is the drugs combination safe for the participants? * Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination. Participants will: * Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year. * Visit the clinic once every 2 weeks for checkups and tests
This description comes directly from the study's public registry record.
Idit Peretz, MD, MBA · 972-3-9378002 · iditper@clalit.org.il
Salomon M Stemmer, MD, Professor of Medicine · 972-3-9378002 · shtemers@clalit.org.il
Always discuss trial participation with your own doctor first.
| Davidoff cancer center, RMC | Petah Tikva, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06940349